维普期刊资源整合服务平台（V6.5）

214篇 您的检索式：作者名="Hanauer SB"

选中清除导出查看参考文献查看引证文献引用追踪共11页首页上一页第1页下一页末页 /11 跳转

	题名	作者	年代	出处	被引量
1	生物学疗法在亚洲炎症性肠病患者中的应用前景显示文摘在不断揭秘炎症性肠病(IBD)发病机制的过程中,发现越来越多的具有治疗干预作用的靶点。目前一般认为溃疡性结肠炎(UC)与克罗恩病(CD)均是肠道对尚未明确的环境触发因素发生过度免疫反应所致。这一概念开启了发展针对肠道微观生物医学(the intestinal microbiome)进行干预治疗的设想。	Hanauer SB 郑家驹(译)	2008	中华消化杂志2008，28，12：	2
2	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial显示文摘	HANAUER SB FEAGAN BG LICHTENSTEIN GR	2002	Lancet2002，359，9317：	1
3	Oral Pentasa in the treatment of active Crohn's disease:A meta-analysis of double-blind,placebo-controlled trials显示文摘	Hanauer SB Strmberg U	2004	Clin Gastroenterol Hepatol2004，2，5：	1
4	Review article:high-dose am inosalicylates to induce and maintain remissions in ulcerative colitis显示文摘	Hanauer SB	2006	Aliment Pharmacol Ther2006，24，3：	1
5	Budesonide CIR capsules (once or twice daily divided-dose ) in active Crohn' s disease : a randomized placebo-controlled study in the United States 显示文摘	Tremaine WJ Hanauer SB Katz S	2002	Am J Gastroenterol2002，97，7：	1
6	Systematic Review:the PharmCokinetic Profiles of Oral MesalaAne Formulations and Mesalazinepro-drugs Used in the Management of Ulcerative Colitis显示文摘	Sandborn WJ Hanauer SB	2003	Aliment Pharmacol Ther2003，17，1：	1
7	Anti-tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety 显示文摘	Sandborn WJ Hanauer SB	1999	Inflamm Bowel Dis1999，5，2：	1
8	Risks and benifits of combining immunosuppressives and biological agents in inflammatory bowel disease:is the synergy worth the risk显示文摘	Hanauer SB		0，，09：	1
9	Management of Crohn's disease in adults显示文摘	Hanauer SB Sandborn W Practice Parameters Committee of the American College of Gastroenterology	2001	Am J Gastroenterol2001，96，3：	1
10	Update on the etiology pathogenesi and diagnosis of ulcerative colitis显示文摘	HANAUER SB	2004	Nat Clin Pract Gastroenterol Hepatol2004，1，1：	1
11	Drug therapy of inflammatory bowel disease显示文摘	Hanauer SB	1996	N Eng J Med1996，334，13：	1
12	Comparative tolerability of treatments for inflammatory bowel disease 显示文摘	Stein RB Hanauer SB	2000	Drug Saf2000，23，5：	1
13	Systematic review:the pharma-cokinetic profiles of oral mesalazine formulations andmesalazine pro-drugs used in the management of ulcerativecolitis显示文摘	Sandborn W J Hanauer SB	2003	Aliment Pharmacol Ther2003，17，1：	1
14	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial显示文摘	SANDBORN WJ HANAUER SB RUTGEERTS P	2007	Gut2007，56，9：	1
15	Human antl-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease : The CLASSIC-I Trial显示文摘	HANAUER SB SANDBORN WJ RUTGEERTS P	2006	Gastroenterology2006，130，2：	1
16	Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis 显示文摘	Hanauer SB	2006	Aliment Pharmacol Ther2006，24，3：	1
17	A Short -term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor Al- pha for Crohn's Disease cA2 Study Group显示文摘	Targan SR Hanauer SB Van Deventer SJ	1997	N Engl J Med1997，337，：	1
18	Sustained steroid-free clinical remission in patients with moderate to severe Crohn's disease treated with adalimumab 显示文摘	HANAUER SB KAMM MA COLOMBEL JF	2006	Am J Gastroenterol2006，101，46：	1
19	Intravenous cyclosporin in ulcerative colitis: a five-year experience显示文摘	Cohen RD Stein R Hanauer SB	1999	Am J Gastrcenterol1999，94，6：	1
20	Comparative tolerability of treatments for inflammatory bowel disease 显示文摘	Stein RB Hanauer SB	2000	Drug Saf2000，23，5：	1

返回顶部每页显示：

共11页首页上一页第1页下一页末页 /11 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示